India, Aug. 15 -- Over the last three decades, the pharmaceutical industry has fundamentally changed the trajectory of HIV. What was once a fatal diagnosis is now a manageable chronic condition for millions, thanks to continuous innovation in anti-retroviral (ARV) therapy. But from where I sit, I am acutely aware that discovery is only half the story. The real test of our leadership as an industry lies in how effectively those breakthroughs travel from the lab bench to the patient.

Today, more than 25 million people rely on uninterrupted ARV treatment, most of them in low- and middle-income countries. At this scale, access is no longer a downstream problem - it is the core outcome by which our success must be judged. Scientific excellenc...